Biomarkers in Barrett's esophagus

Gastrointestinal Endoscopy Clinics of North America

Volumn 13, Issue 2, 2003, Pages 369-397

  Reid, Brian J ^a,b   Blount, Patricia L ^a,b   Rabinovitch, Peter S ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; PROTEIN P16; PROTEIN P53;

ANEUPLOIDY; BARRETT ESOPHAGUS; CANCER RISK; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME ABERRATION; CLINICAL TRIAL; CLONE; CONTROLLED CLINICAL TRIAL; DISEASE MARKER; DISEASE SEVERITY; DNA SEQUENCE; DYSPLASIA; ENDOSCOPIC BIOPSY; FLOW CYTOMETRY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC STABILITY; GENOMICS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; METHYLATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SEQUENCE ANALYSIS; TETRAPLOIDY; VALIDATION PROCESS;

EID: 0037841818     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5157(03)00006-0     Document Type: Review

References (123)

1. Krishnadath K, Reid B, Wang K. Biomarkers in Barrett esophagus. Mayo Clin Proc 2001; 76:438-46.
2. van Lieshout EM, Jansen JB, Peters WH. Biomarkers in Barrett's esophagus. Int J Oncol 1998; 13:855-64.
3. Winkelstein A. Peptic esophagitis: a new clinic entity. JAMA 1935;104:906-9.
4. Barrett NR. Chronic peptic ulcer of the oesophagus and "oesophagitis". Br J Surg 1950;38: 175-82.
5. Allison PR, Johnstone AS. The oesophagus lined with gastric mucosa membrane. Thorax 1953; 8:87-101.
6. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975;70:826-35.
7. Devesa SS, Blot WJ, Fraumeni Jr JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
8. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.
9. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
10. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9.
11. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
12. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
13. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285: 2331-8.
14. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000;46:574-7.
15. Sharma P, Falk G, Weston A, et al. Natural history of low grade dysplasia-an infrequent finding which usually regresses-preliminary results from the Barrett's Esophagus Study. Gastroenterology 2002;122:A20.
16. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
17. Sullivan Pepe M, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
18. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
19. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
20. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis 2000;21: 379-85.
21. Wong DJ, Paulson TG, Prevo LJ, et al. p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61: 8284-9.
22. Barrett MT, Galipeau PC, Sanchez CA, et al. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996;12:1873-8.
23. Dolan K, Garde J, Gosney J, et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 1998;78:950-7.
24. Hammoud ZT, Kaleem Z, Cooper JD, et al. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996;56:4499-502.
25. Tarmin L, Yin J, Zhou X, et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 1994;54:6094-6.
26. Muzeau F, Flejou JF, Thomas G, Hamelin R. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. Int J Cancer 1997;72:27-30.
27. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53 mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-7.
28. Hamelin R, Flejou JF, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-8.
29. Gleeson CM, Sloan JM, McGuigan JA, et al. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995;55:3406-11.
30. Schneider PM, Casson AG, Levin B, et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996; 111:323-31; discussion, 331-3.
31. Campomenosi P, Conio M, Bogliolo M, et al. p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev 1996;5:559-65.
32. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000;60:5021-6.
33. Bian YS, Osterheld MC, Fontolliet C, et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002;122:1113-21.
34. Klump B, Hsieh CJ, Holzmann K, et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998;115:1381-6.
35. Neshat K, Sanchez CA, Galipeau PC, et al. Barrett's esophagus: a model of human neoplastic progression. In: Cold Spring Harbor Symposia on Quantitative Biology, Volume 59. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1995. p. 577-83.
36. Reid BJ, Barrett MT, Galipeau PC, et al. Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev 1996;5(Suppl):57-65.
37. Deville P, Cleton-Jansen A-M, Cornelisse CJ. Ever since Knudson. Trends Genet 2001;17: 569-73.
38. Knudson Jr AG. Genetics of human cancer. Annu Rev Genet 1986;20:231-51.
39. Mei R, Galipeau PC, Prass C, et al. Genome-wide detection of loss of heterozygosity with single nucleotide polymorphisms and high density DNA arrays. Genome Res 2000;10: 1126-37.
40. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/ p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-73.
41. Galipeau PC, Prevo LJ, Sanchez CA, et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999;91:2087-95.
42. Hartwell LH, Culotti J, Pringle JR, Reid BJ. Genetic control of the cell division cycle in yeast. Science 1974;183:46-51.
43. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
44. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
45. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
46. Fukasawa K, Choi T, Kuriyama R, et al. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-7.
47. Pihan GA, Purohit A, Wallace J, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998;58:3974-85.
48. Schmidt HG, Riddell RH, Walther B, et al. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol 1985;110:145-52.
49. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 1978;70:1-5.
50. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
51. Alikhan M, Rex D, Khan A, et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999;50: 23-6.
52. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
53. Polkowski W, van Lanschot JJ, Ten Kate FJ, et al. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 1995;4: 163-71.
54. Polkowski W, Baak JP, van Lanschot JJ, et al. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol 1998;184:161-8.
55. Sagan C, Flejou JF, Diebold MD, et al. Observer variation in the diagnosis of dysplasia in Barrett's mucosa. Gastroenterol Clin Biol 1994;18:D31-4.
56. Ormsby AH, Perras RE, Henricks WH, et al. Interobserver variation in Barrett's (BE) related high-grade dysplasia (HGD) and superficial adenocarcinoma: can it be improved using uniform pathologic criteria? Gastroenterology 2000;118:A3764.
57. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
58. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
59. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
60. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
61. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280:1747-51.
62. Dimick JB, Cattaneo SM, Lipsett PA, et al. Hospital volume is related to clinical and economic outcomes of esophageal resection in Maryland. Ann Thorac Surg 2001;72:334-41.
63. Patti MG, Corvera CU, Glasgow RE, Way LW. A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998;2:186-92.
64. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-37.
65. Sharma P, Weston A, Falk G, et al. Can two upper endoscopies negative for dysplasia eliminate the need for future surveillance in patients with Barrett's esophagus? Am J Gastroenterol 2001; 96:S36.
66. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93:1028-32.
67. Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-62.
68. Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointest Endosc 2000;52:197-203.
69. Ofman JJ, Lewin K, Ramers C, et al. The economic impact of the diagnosis of dysplasia in Barrett's esophagus. Am J Gastroenterol 2000;95:2946-52.
70. Eloubeidi MA, Homan RK, Martz MD, et al. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting. Am J Gastroenterol 1999;94:2033-6.
71. Weston AP, Banerjee SK, Persons DL, et al. p53 positivity in low-grade dysplasia (LGD) in Barrett's esophagus: marker predictive of progression to cancer or multifocal high-grade dysplasia (mHGD). Am J Gastroenterol 1999;94:2603.
72. Sontag SJ, Schnell T, Chejfec G, et al. Barrett's, low grade dysplasia and fear; yearly endoscopy is not justified: surveillance every 2-3 years detects all cancers early. Gastroenterology 1999; 116:A316.
73. Herbst JJ, Berenson MM, McCloskey DW, Wiser WC. Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). Gastroenterology 1978;75:683-7.
74. Gray MR, Hall PA, Nash J, et al. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992;103:1769-76.
75. Pellish LJ, Hermos JA, Eastwood GL. Cell proliferation in three types of Barrett's epithelium. Gut 1980;21:26-31.
76. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1-11.
77. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
78. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999;117: 327-35.
79. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
80. Kitahara K, Yasui W, Yokozaki H, et al. Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines. J Exp Ther Oncol 1996;1:7-12.
81. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996;5:457-9.
82. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21.
83. Neshat K, Sanchez CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
84. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
85. Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997;79:425-32.
86. Moore JH, Lesser EJ, Erdody DH, et al. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer 1994;56:487-93.
87. Kubba AK, Poole NA, Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci 1999;44:659-67.
88. Blount PL, Galipeau PC, Sanchez CA, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994;54:2292-5.
89. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 1996;93:7081-4.
90. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
91. Muzeau F, Flejou JF, Potet F, et al. Profile of p53 mutations and abnormal expression of P53 protein in 2 forms of esophageal cancer. Gastroenterol Clin Biol 1996;20:430-7.
92. Younes M, Ertan A, Lechago LV, et al. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997;42:697-701.
93. Carlson N, Lechago J, Richter J, et al. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol 2002;97:1340-5.
94. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 1999;9:482-91.
95. Robaszkiewicz M, Hardy E, Volant A. Analyse du contenu cellulaire en ADN par cytometrie en flux dans les endobrachyoesophages. Gastroenterol Clin Biol 1991;15:703-10.
96. McKinley MJ, Budman DR, Grueneberg D, et al. DNA content in Barrett's esophagus and esophageal malignancy. Am J Gastroenterol 1987;82:1012-5.
97. Fennerty MB, Sampliner RE, Way D, et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989;97:815-20.
98. Menke-Pluymers MB, Mulder AH, Hop WC, et al. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 1994;35:1348-51.
99. Gimenez A, Minguela A, Parrilla P, et al. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Cancer 1998;83:641-51.
100. Montgomery EA, Hartmann DP, Carr NJ, et al. Barrett esophagus with dysplasia. Flow cytometric DNA analysis of routine, paraffin-embedded mucosal biopsies. Am J Clin Pathol 1996; 106:298-304.
101. Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology [published erratum appears in Cytometry 1993;14:842]. Cytometry 1993;14:472-7.
102. Ormerod MG, Tribukait B, Giaretti W. Consensus report of the task force on standardisation of DNA flow cytometry in clinical pathology. DNA Flow Cytometry Task Force of the European Society for Analytical Cellular Pathology. Anal Cell Pathol 1998;17:103-10.
103. Rabinovitch PS. Practical considerations for DNA content and cell cycle analysis. In: Bauer KD, Duque RE, Shankey TV, editors. Clinical flow cytometry: principles and applications. Baltimore: Williams and Wilkins; 1992. p. 117-42.
104. D'Hautcourt JL, Spyratos F, Chassevent A. Quality control study by the French Cytometry Association on flow cytometric DNA content and S-phase fraction (S%). The Association Francaise de Cytometrie. Cytometry 1996;26:32-9.
105. Tirindelli Danesi D, Spano M, Altavista P, et al. Quality control study of the Italian Group of Cytometry on flow cytometry DNA content measurements: II. Factors affecting inter- and intralaboratory variability. Cytometry 1997;30:85-97.
106. Bergers E, Montironi R, van Diest PJ, et al. Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometry DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Hum Pathol 1996;27:553-60.
107. Duigou F, Herlin P, Marnay J, Michels JJ. Variation of flow cytometric DNA measurement in 1,485 primary breast carcinomas according to guidelines for DNA histogram interpretation. Cytometry 2000;42:35-42.
108. Elavathil LJ, Celebre G, McFarlane D. Reproducibility of DNA ploidy and S-phase values from paraffin-embedded tissue. Anal Quant Cytol Histol 1996;18:316-22.
109. Alanen KA, Joensuu H, Klemi PJ. Autolysis is a potential source of false aneuploid peaks in flow cytometric DNA histograms. Cytometry 1989;10:417-25.
110. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998;34:257-63.
111. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
112. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
113. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85-92.
114. Vaughan TL, Kristal AR, Blount PL, et al. NSAID use, BMI, and anthropometry in relation to genetic and cell cycle abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002;11:745-52.
115. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000;119:624-30.
116. Krishnadath KK, Wang KK, Taniguchi K, et al. p53 mutations in Barrett's esophagus predict poor response to photodynamic therapy. Gastroenterology 2001;120:A413.
117. Foultier MT, Vonarx-Coinsman V, de Brito LX, et al. DNA or cell kinetics flow cytometry analysis of 33 small gastrointestinal cancers treated by photodynamic therapy. Cancer 1994; 15:1595-607.
118. Reid BJ, Blount PL, Feng Z, et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:3089-96.
119. Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170-6.
120. Peters JH, Clark GWB, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-22.
121. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997;92:586-91.
122. Ofman JJ, Shaheen NJ, Desai AA, et al. The quality of care in Barrett's esophagus: endoscopist and pathologist practices. Am J Gastroenterol 2001;96:876-81.
123. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000;321:1252-5.